Altman's New Brain-Computer Interface Venture: Gene Editing and Ultrasound

OpenAI CEO Sam Altman is involved in a brain-computer interface company, Merge Labs, exploring a novel approach combining gene therapy and ultrasound. The method involves genetically modifying brain cells and using an implanted ultrasound device to detect and modulate activity in these cells. This differs from Elon Musk's Neuralink, which uses electrical signals. Altman aims to use this technology to control ChatGPT with his thoughts. The project is in early stages, seeking $250 million in funding at an $850 million valuation.